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THE TRANSDUCTION OF DENDRITIC CELLS FOR THE IMMUNOTHERAPY OF
CANCER. J. Mark Sloan, Michael Kershaw, Chris Touloukian, Rejean Lapointe, Paul
Robbins, Nicholas Restifo and Patrick Hwu. Surgery Branch, National Cancer Institute,
National Institutes of Health, Bethesda, MD. (Sponsored by Ira Mellman, Department of
Cell Biology, Yale University School of Medicine, New Haven, CT.)

The unique antigen presenting capabilities of dendritic cells make them an
attractive means with which to initiate an anti-tumor immune response. Using dendritic
cells transduced with tumor antigens for immunotherapy has several theoretical
advantages over peptide-pulsed or tumor lysate-pulsed dendritic cells. Since both CD4+
and CD8+ T cells have been shown to play important roles in anti-tumor immunity, one
potential advantage is the possibility that transduced dendritic cells are capable of
presenting multiple and undefined epitopes on both class I and class II MHC molecules.
To test this theory, we inserted the human tumor antigen gplOO, which has known class I
and class II epitopes, into dendritic cells derived from the bone marrow of mice
transgenic for HLA-DRp 1*0401.

The human gplOO gene was inserted using either

adenovirus or a VSV-G pseudotyped retrovirus. A murine CD8+ T cell clone recognizing
an H-2Db restricted epitope for gplOO and a murine CD4+ T cell line recognizing an
HLA-DRp 1*0401 restricted gplOO epitope were then used in a cytokine release assay to
test for reactivity against the adenovirally or retrovirally transduced dendritic cells. Both
the CD8+ and CD4+ gplOO specific T cell lines were able to recognize the gplOO
transduced dendritic cells significantly more than GFP transduced controls, lending
support to the use of gene-modified dendritic cells as a means to simultaneously initiate a
CD4+ and CD8+ anti-tumor response. Additionally, VSV-G pseudotyped retroviral
vectors were investigated as a means of inserting multiple genes into dendritic cells. This
ability, combined with the ability to immunize mice against genes expressed by
transduced dendritic cells, is explored as a potential means of antigen discovery and
direct immunization against tumor.
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Introduction
Cancer Immunotherapy
Evidence that the immune system can recognize and attack tumors in humans and
murine models is abundant and compelling. For instance, administration of the cytokine
interleukin-2 (IL-2) to patients with metastatic melanoma can induce tumor regression in
15 to 20% of patients, almost half of whom experience a complete response1. Of the
complete responders, 80% remain in lasting remission, and are apparently cured of their
disease2. IL-2 has no primary effect on the tumor; its action is mediated by the cytokine’s
ability to initiate a cellular immune response against antigens presented on the surface of
the melanoma cells.
Despite a decade of intensive effort, characterizing these cellular immune
responses has been difficult. These difficulties reflect the complex nature of the afferent
anti-tumor immune response, and its elaborate interplay with T cell tolerance and
autoimmunity. A successful anti-tumor response requires that a quiescent, tumor-reactive
T lymphocyte recognize a tumor antigen, attain the state of activation required to
proliferate, than traffic to and exert a cytolytic effect on an autologous tumor.

Strategies

used to produce this response can be divided into either active or passive approaches.
Direct immunization against tumor antigens is known as active immunotherapy, while
passive (adoptive) immunotherapy refers to the transfer of T cells with pre-existing
reactivity to tumor antigens3.
The majority of cancer immunotherapy work has focused on the identification and
molecular characterization of melanoma tumor antigens. Antigens are identified using
anti-tumor T lymphocytes to screen cDNA libraries derived from cancer cells. These
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anti-tumor T lymphocytes are either grown from resected tumors to yield tumor
infiltrating lymphocytes (TIL), or generated through repetitive in vitro stimulation of
peripheral blood mononuclear cells (PBMC) with tumor cells in the presence of IL-2.
Tumor antigens can be classified into four categories:
1) Mutated antigens unique to both patient and individual tumor
2) normal, non-mutated self-proteins presented on the surface of differentiated cells
3) embryonic or quiescent genes reactivated and expressed after carcinogenesis
4) antigens resulting from aberrant splicing or post translational protein modification
prior to antigen processing
Of these antigen categories, the second has received the most scrutiny. The majority of
melanoma antigens identified to date are proteins expressed in normal melanocytes, and
are present in the majority of malignant melanomas.
Discouragingly, little success has been made towards generalizing from work on
melanoma to more common cancers, such as breast, ovarian and colon cancer. A major
stumbling block has been the lack of defined T cell antigens in these tumors, which have
been resistant to the aforementioned antigen discovery techniques4. It is of considerable
interest, therefore, to develop methods that would enable the identification and
characterization of antigens in common tumors.

Dendritic Cells and Cancer Immunotherapy
Dendritic cells (DCs) play a pivotal role in the initiation of immunity5. Because
of their unique repertoire of cell surface molecules, antigen processing machinery, and
tissue distribution, dendritic cells serve as the principal activators of quiescent T cells
(figure 1). These antigen presenting capabilities make dendritic cells an attractive means
with which to initiate an anti-tumor immune response. Considerable effort has been
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directed towards immunizing patients and murine models using dendritic cells loaded
with tumor antigens, and many groups have documented their ability to induce protective
and therapeutic anti-tumor immunity6 7 8.
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Figure 1 Dendritic cells and the immune response. Dendritic cells capture and process potential
antigens, then present them to T cells in the appropriate co-stimulatory context. Figure from Banchereau,
1998.

Most studies endeavor to immunize patients with DCs that have been loaded with
tumor antigens ex vivo. Common methods of antigen loading DCs include pulsing them
with defined peptide epitopes or with tumor lysates9. These methods will primarily result
in antigen presentation on MHC class I and class II molecules, respectively. However,
both CD8+ and CD4+ T cells appear to play crucial roles in robust anti-tumor responses10
11. It is therefore advantageous to find a method of loading and administering dendritic
cells which results in the simultaneous presentation of class I and class II tumor antigen
epitopes. Since certain endogenous antigens have been shown to be efficiently presented
on MHC class II molecules12 B, the use of gene-modified DCs may be a way to present a
tumor antigen on both MHC class I and class II molecules.

8

Gene-Modified Dendritic Cells in Cancer Immunotherapy
Groups have been able to insert genes into both human14 and murine1" dendritic
cells using retroviral vectors16, adenoviral vectors17, or direct transfection of genetic
material18. These studies demonstrate the ability of gene-modified dendritic cells to
induce protective and therapeutic anti-tumor immunity in mice.

Most of this work was

done with highly immunogenic foreign model antigens. For example, mice can readily
be immunized using dendritic cells transduced with the beta galactosidase gene; these
animals are then protected from intravenous challenge with the highly immunogenic, beta
galactosidase expressing tumor CT26.C12519. As with other methods of active and
passive immunotherapy, treatment of autologous tumors using transduced DCs is much
more difficult than treating tumors containing foreign antigens. The paucity of
experiments demonstrating treatment of entirely autologous tumors supports this
assertion. Those that do are often plagued by technical oversights, such as challenging
mice with tumors cultured in fetal calf serum after those animals have been vaccinated
using dendritic cells grown in calf serum. In this situation, the protection conferred
against tumor challenge is related to anti-calf serum immunity, and has little to do with
antigen specific anti-tumor immunity initiated by the dendritic cells.
Several groups have observed that immunizations with transduced dendritic cells
require CD4+ T cell help for optimal anti-tumor effects20. However, existing evidence for
anti-tumor CD4+ T cell activation by gene-modified dendritic cells is indirect. Using the
OVA model antigen, a group has demonstrated that CD4+ T cell depletion abolishes
tumor protection induced by transduced DCs21. It is unclear whether this reflects
presentation of antigen from transduced DC directly to CD4+ T cells, or results from cross
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presentation of antigen secreted from the transduced cell which is then processed by a
native APC as an exogenous antigen. Direct evidence for the presentation of tumor
antigen to CD4+ T cells by transduced dendritic cells is lacking.

Potential Advantages of Immunization with Transduced Dendritic Cells Over
Peptide Pulsed Dendritic Cells
By introducing a gene encoding an antigen into dendritic cells, one allows the
antigen presenting cell (APC) to perform its own antigen processing and presentation. In
addition to the possibility that gene-modified dendritic cells can present transgeneencoded class II epitopes to CD4+ T cells, this method has several other potential
advantages over peptide-pulsed DCs. All possible epitopes within the antigen would be
available for processing and presentation, obviating the need to laboriously define and
synthesize precise peptide epitopes. The epitopes in gene-modified DCs would be
subjected to normal post-translational processing prior to presentation, thereby acquiring
modifications that could influence epitope recognition. Finally, since the antigen
continues to be expressed over time, transduced cells may sustain epitope presentation
longer than their peptide pulsed counterparts.

The Transduction of Dendritic Cells
The methods currently available for the gene-modification of dendritic cells are:
transfection with DNA or RNA, adenoviral transduction and retroviral transduction.
Transfection and other non-viral methods of gene transfer into dendritic cells is difficult,
with approximately 2% gene transfer efficiency in our experience, though others report
higher numbers22. Transgene expression in a transfected cell tends to be short-lived,
especially if RNA is used as the transfected material.
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Adenovirus can insert genes into DCs with efficiencies approaching 100%.

It has

the additional advantage of being able to transduce non-dividing cell populations. The
adenovirally-inserted transgene resides episomally within the target cell. As a result,
transgene expression will be diluted and lost if the target cell proliferates after
transduction. Adenoviral vector construction is technically challenging; the cost and
labor involved in creating large numbers of adenoviral vectors is nearly prohibitive.
Retroviral vectors offer a unique set of advantages and disadvantages. Although
dendritic cell transduction with retroviral vectors is more challenging than with
adenoviral vectors, retroviral vectors are also capable of attaining high levels of gene
transfer into DCs. Retroviruses can only transduce dividing cells, but do so stably, so
that the progeny of transduced cells also contain the transgene. Since a mature dendritic
cell does not proliferate, one must retrovirally transduce dividing hematopoietic
progenitor cells, then differentiate them in vitro into dendritic cells. In comparison with
adenoviral vectors, it is relatively easy to engineer a retroviral vector containing the
desired transgene.

VSV-G Pseudotyped Retroviral Vectors
Several limitations of traditional retroviral vectors derived are circumvented
through the use of Moloney murine leukemia virus (MMLV) based retroviral vectors
pseudotyped with vesicular stomatitis virus G (VSV-G) glycoprotein. A retroviral
pseudotype is created when the genome of one virus is encapsidated by the envelope
protein of a second virus (Figure 2). In this situation, the host range is determined by the
viral envelope protein. The VSV-G envelope protein has several properties that make it
attractive for use as a retroviral pseudotype. In contrast to other viral envelopes, which

depend on specific protein receptors for viral entry and fusion, the VSV envelope proteins
use phosphatidylinositol, a ubiquitous phospholipid, as their receptor23, thus enabling the
pseudotyped virus to fuse directly with the target cell membrane. This remarkable
property gives VSV-G pseudotyped vectors a virtually unlimited target cell range.

VSV-G
Envelope
Proteins

Genome, gag
and pol from
MMLV

^

Figure 2 Retroviral Pseudotypes. VSV-G pseudotyped retroviruses have use the genome, gag and pol of
the MMLV, but have a VSV envelope, making a virus an unlimited host cell range. [Figure adapted from
Heaphy, 199724]

The stability of the VSV envelope provides several additional advantages. While
normal amphotropic/ecotropic retroviral envelopes cannot withstand the force of
ultracentrifugation, VSV pseudotypes can be concentrated to extremely high titers25.
High viral titers are crucial for obtaining maximal gene transfer efficiency, especially in
difficult to transduce cell populations, such as dendritic cells.

Traditional retroviral

envelopes are thermolabile, and must be used immediately after collection. The VSV
envelope, in contrast, has the stability needed to withstand a freeze thaw cycle. Although
this is largely a matter of convenience, it allows for the generation and storage of large
amounts of standardized pseudotyped virus.
Unlike adenoviral vectors and some retroviral systems, the VSV-pseudotyped
system expresses no viral proteins in the target cell. After viral entry and reverse

transcription the transgene is stably integrated into the target cell genome. The highly
immunogenic VSV-G envelope protein is lost as the target cell proliferates. Since a
tumor antigen will be overlooked by the immune system in favor of an immunodominant
antigen, it is important to keep the antigen presenting cell free of foreign, potentially
immunodominant antigens.

This is a theoretical contraindication for using adenoviral or

certain retroviral vectors, which co-express viral proteins in the host cell, for immunemediated gene therapy.

The Processing of Endogenous Antigens on the Class II Pathway
MHC class I and MHC class II molecules primarily associate with peptides from
different cellular compartments. Peptides bound to MHC class I molecules come
predominantly from proteins degraded in the cytoplasm, while peptides bound to MHC
class II molecules are mostly derived from exogenous or intravesicular sources (figure
3)26. In this manner, they are able to present the antigen to the subset of T cells best
equipped to destroy a pathogen residing in a given compartment. A more complicated
picture of antigen processing is emerging, in which antigen presenting cells, and dendritic
cells in particular, are able to sample proteins from either compartment for presentation
on class I and class II molecules27 28.
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Figure 3 Endogenous and Exogenous antigen presentation pathways. The MHC class II and class I
molecules primarily associate with exogenous or cytoplasmic pathogens, respectively. Despite this,
antigen presenting cells may be able to sample endogenously expressed proteins on MHC class II
molecules. [Adapted from Rosenberg, 1996]

The maturity of dendritic cells is known to have a substantial impact on their
MHC II expression29. Upon activation, immature dendritic cells experience a reduction in
endocytic activity and simultaneously transport intracellular peptide-MHC II complexes
to the cell surface. Because of this dramatic reorganization, the activation state of the
dendritic cell could have considerable impact on the MHC class II presentation of
endogenous antigens. In vivo, bacterial products (LPS), inflammation markers (TNFa)
or T cell interaction via CD40L are thought to be responsible for DC activation. For bone
marrow derived dendritic cells, any physical manipulation appears to mature the DCs.
The cell surface markers displayed on the dendritic cells used in this experiment, even
without biochemical manipulation, are those of mature dendritic cells. The degree to
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which further activation can be induced by addition of membrane-bound CD40L, in the
form of contact with 3T3 cells expressing CD40L is unknown.

The gplOO Antigen and the Melanosome Transport Signal
Several requirements must be fulfilled in order to definitively demonstrate the
simultaneous presentation of transgene-encoded epitopes to CD4f and CD8+ T cells. The
antigen used must contain well-defined class I and class II epitopes.

Clonal CD4+ and

CD8+ T cell populations specific for these epitopes and amenable to in vitro work must
exist. Ideally, the antigen used should be a human tumor antigen in order to have
immediate clinical relevance.
The nonmutated melanocyte differentiation antigen, gplOO, fulfills these criteria.
In humans, gplOO is expressed by normal melanocytes and the majority of malignant
melanomas30. A close murine homologue for gplOO (also known as pmel) has been
described31. The gplOO class I epitope is restricted by H-2Db and located at amino acids
25-33. Human and mouse gplOO differ by 3 amino acids at these positions (figure 4), but
either can be recognized by mouse CD8f T cells specific for this epitope32. Human gplOO
was used for these experiments. The class II epitope is restricted by HLA-DRB 1*0401
and located at amino acids 44-5933. Therefore, a dendritic cell derived from a C57BL/6
mouse transgenic for human HLA-DRB1 *0401 and expressing human gplOO should be
able to present both the class I (25-33) and class II (44-59) gplOO epitopes.
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H-21X epitope (aa 25-33)
mouse: EGSRNQDVVL
human: KVPRNQDWL

HI A -ORBI*0401 epitope (aa 44-5*4)
human: WNRQLYPEWTEAQRLD
Melanosomal Transport Signal
ENSPLL

<=0

gplOO
Figure 4 The gplOO tumor antigen. Both human and murine gplOO have well-defined MHC class I and
class II epitopes, and a melanosome transport signal.

Like other melanosome membrane glycoproteins, gplOO contains a melanosome
transport signal (MTS)34. This transport signal has been shown to traffic antigens to the
endocytic pathway for class II presentation35. The MTS would be expected to enhance
the class II presentation of endogenously expressed gplOO protein. Other groups use
lysosomal-associated membrane protein (LAMP)36 or invariant chain (Ii)37 targeting
signals in an effort to increase class II presentation of endogenous proteins. The relative
efficiency of these targeting signals for increasing class II presentation of endogenous
antigens is unknown.

The Retroviral Transduction of Dendritic Cells with Pools of Genes
Many of the experiments in this project depend on the ability to simultaneously
transduce cells with more than one gene. The efficiency of DNA or RNA co-transfection
into DCs becomes vanishingly small when working with multiple transgenes. Likewise,
using adenovirus for multiple gene insertions is impractical, given the aforementioned
difficulties in vector construction and that toxic levels of adenovirus would be required
for multiple transductions. Multiple gene insertions using a retrovirus are only allowed in
certain situations. In nature, only one retrovirus can infect a cell before others are
excluded. This is secondary to the sequestration of required binding and fusion proteins
after entry of the initial virus. This mechanism can be circumvented by using replicationincompetent retroviruses. VSV-G pseudotyped virions are ideally suited to insert
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multiple genes into a single cell, since they do not require surface proteins on the target
cell for infection; therefore, their entry is not limited by receptor saturation. The ease of
retroviral vector construction in the VSV system aids in the development of retroviral
libraries. By simultaneously infecting cells with supernatant containing a mixture of
virions, each with a unique transgene, one can create cells expressing extremely large
numbers of inserted genes.
The behavior of individual cells containing multiple transgenes, or multiple copies
of a single transgene, all of which are driven by highly active viral promoters, has not
been studied in great detail. In this situation, competition for ribosomes and other
cellular machinery and resources certainly plays a role in limiting the expression of
individual transgenes. For instance, if 1000 copies of gene A (driven by a CMV
promoter) were inserted into a single cell, large amounts of protein A would be produced,
perhaps to the exclusion of the cell’s normal housekeeping functions. The situation is
less clear when 1000 unique copies of different transgenes are inserted into a cell. Even
after each has successfully integrated into the host genome, these transgenes would
compete with each other for transcription and translation. At some point, a single gene in
an increasingly large pool of transgenes would be expressed at either undetectable levels
or not at all.
The complexity increases when one applies this situation to an antigen presenting
cell, and asks which antigens in a dendritic cell saturated with multiple transgenes will be
presented to T cells. It is the function of an APC to present foreign antigens at a
sufficient level even when sampling from amongst much more numerous native proteins.
It does so through a combination of stochastic efficiency and intrinsic preference of the
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immunoproteasome, TAP protein, and other components of the antigen processing
machinery for proteins that appear foreign38. It is thus intuitively favorable to presume
that a DC transduced with a pool of genes will be able to present most potential antigens
encoded in that pool, but will do so only haphazardly if the pool is so large that individual
transgenes are not all expressed.

Transduced Dendritic Cells for Antigen Discovery
Beyond the potential importance of active immunotherapy by vaccination with
gene-modified dendritic cells, there are several possible in vitro applications of
transduced dendritic cells. These applications could make gene-modified dendritic cells
important tools for antigen discovery and for gaining insight into the anti-tumor immune
response.
It is a strong possibility that some antigens are better than others, although we
know little about what it is that makes a good tumor rejection antigen. Many variables
could affect the ability of an antigen to initiate and sustain an anti-tumor response. These
variables include the antigen category (i.e. whether it is a mutated antigen or a normal
differentiation antigen), the number of epitopes on an antigen, as well as their type,
dominance and affinity for the associated MHC molecules. Also important is the level of
antigen expression and its heterogeneity within the tumor, as well as the susceptibility of
a particular antigen to loss during immunoselection.

If the antigen is a normal

differentiation antigen, its expression level and pattern in normal tissues will impact the
available T cell repertoire and tolerance. Finally, the presentation context and co¬
stimulatory setting of the antigen is crucial to promoting an afferent immune response.
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As described above, antigen discovery has previously been limited to seeking the
epitopes recognized by tumor infiltrating lymphocytes (TIL) or PBMC from mixed
tumor-lymphocyte cultures. These methods are a convenient means to define an antigen,
although they may only be finding a particular subset of antigens. In fact, this subset
contains perhaps the worst antigens to characterize, as tumors generally continue to grow
despite the presence of endogenous or adoptively transferred TIL specific for these
antigens. A more comprehensive approach would be one that uses tumor rejection itself
as the means for antigen identification.
The ability to efficiently transduce dendritic cells with pools of genes, combined
with the ability to successfully immunize an animal using transduced dendritic cells
makes such an approach possible.

By immunizing mice with dendritic cells transduced

with pools of genes derived from a tumor cDNA library, and then challenging with the
corresponding tumor, one could identify pools of genes that confer tumor protection.
These pools must contain one or more rejection antigens. Individual antigens could then
be identified through repeated rounds of sub-pooling and tumor challenge (figure 5).
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Tumor cell

1

Immunization
(1 pool/mouse)

Tumorigenic dose of
fresh tumor cells
Mouse immunized against
antigens encoded in cDNA pool

Tumor challenge

Protection from tumor challenge implies rejection
antigen is present in cDNA pool used for transduction

Sub-pool genes in
protective pool and
repeat experiment until
rejection antigen is
identified

Figure 5 A method of antigen identification based on tumor protection. Dendritic cells are transduced
with pools of genes derived from a tumor cDNA library. Mice are immunized with the transduced cells,
and then challenged with tumor. In the cases where mice are protected from tumor challenge, there must
be a tumor rejection antigen present in the pool used to transduce the DCs. The particular antigen
responsible for protection can be identified through repeated rounds of sub-pooling.

This pooling method of antigen discovery has several potential advantages over
conventional antigen finding methods. Since the most protective antigens would
presumably immunize even in very large pools (with corresponding low levels of
expression within the APC), the best tumor rejection antigens may be found first. The
antigens found using this approach may provide insight into the nature of a rejection
antigen. For example, if all the antigens discovered were mutated proteins, it may speak
to the inability of animals to mount an equally efficient response against non-mutated
differentiation antigens. This would represent a major paradigm shift in current thought
on tumor antigens, as it was always hoped that the continued growth of tumors in the
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presence of TIL known to recognize non-mutated antigens reflected the inadequate
activation state or numerical advantage of the TIL, rather than anything intrinsically
wrong with differentiation antigens themselves.
Since a retroviral library can be made from any tissue type, this approach may
also be a means to discover antigens for more common, less immunogenic tumors. This
would be an extremely valuable asset, as it would allow antigen-based immunotherapy to
move away from melanoma to more important cancers. In addition, work using
appropriate animal models may lead directly to clinically relevant antigens because
murine tumor antigens often have human homologues,. This point is illustrated by the
murine melanoma antigens mgplOO, mtrpl and mtrp2, which all have homologous
human antigens39.

Potential Uses of Dendritic Cells Transduced with Tumor cDNA Libraries
for Direct Immunization Against Tumor
The ability to actively immunize animals and patients with dendritic cells
expressing pools of transgenes has many potential applications. It is possible that one
could directly immunize against a tumor using dendritic cells that have been transduced
en masse with an entire tumor cDNA library. This would represent the ultimate in
customized immunotherapy, where potential rejection antigens come directly from the
cDNA library of the specific tumor to be treated. This approach would be a means to
take advantage of mutated, tumor and patient specific antigens, as well as shared
differentiation antigens. The method has the added advantage of being applicable to any
tumor type, regardless of its tissue of origin.
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The possibility for success hinges on the dendritic cell’s ability to process and
present individual antigens even when they are expressed in the presence of more
numerous non-antigenic proteins. Obviously, the more antigens present within the tumor,
the greater the chance of presenting a given antigen at levels visible to the immune
system. Although the amount of potential antigens in a tumor is unknown, the substantial
genetic instability, rapid mutation rate and genetic dysregulation in neoplastic cells could
produce multiple potential antigens.

MATERIALS AND METHODS
VSV-G Pseudotyped Retroviral Vectors and Retroviral Transduction of DCs
The procedure for creating VSV-G pseudotyped virus and infecting target cells is
schematized in Figure 6. Because the VSV-G envelope is toxic to virus-producing cells,
it is not possible to engineer a suitable stable packaging cell line. Therefore, pseudotyped
virus must be created by co-transfecting the transgene encoding retroviral plasmid and the
VSV-G encoding plasmid into cells that constitutively express the gag and pol proteins.
The 293GP cell line is easily transfectable and was developed for this purpose.

22

I M\

CM V Promote

in

'P «
3

Retrovirai construct
with transgcix

Co-Transfection

r

rs o
293GP
’packaging ceil'

rv

->

/

/

RNA
Nucleus

p. o
b

Rc\ erse

V

[ransciiplion

i©

d

{’a£ O ®Po|
V/ K)

t MV
*•

I

Double Sirrtntied DMA

Co-Tiantfcction

Integration

^0 pi'oteiis
Target
(elf

k

*

tWDNA

- l’mnslation
(ytopiasnr

Nucleus

fl

Figure 6 Creation of VSV-G pseudotyped retrovirus. VSV-G pseudotyped retrovirus is created by co¬
transfection of retroviral plasmid and a VSV-G encoding plasmid into a 293 cell constitutively expressing
gag and pol proteins. The pseudotyped virions are then capable of infecting a target cell. Once infected,
the retrovirus undergoes reverse transcription and integration into the host cell genome. [Figure adapted
from Verma, 199840]

A number of retroviral vectors were tested for these projects. The most effective
vectors were those that contained a CMV promoter driving transcription of the provirus
within the packaging cell (data not shown). The pCLNCx construct contains the early
region of the CMV enhancer-promoter fused to the MMLV LTR in the 5’ U3 region41.
Once integrated, the 5’ LTR is responsible for promoting the neomycin resistance gene.
Another CMV promoter is located downstream of the neo gene and drives transcription
of the transgene.
The original plasmid was modified to create a more functional multiple cloning
site (figure 7). Also, a self-inactivating (SIN) form of this plasmid was created by
removing the portion of the U3 region containing the NFkB transcription factor binding
site (figure 8, 9). Since the U3 region is copied to the 5’ end of the provirus during
reverse transcription, this excision greatly reduces neo expression. By removing the
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powerful promoting elements from the 5’LTR, the SIN plasmid is thought to eliminate
promoter interference between the LTR and CMV promoters. The SIN and NON-SIN
versions of this plasmid behaved comparably for dendritic cell transduction, and were
used interchangeably except where noted.

Hindlll-Bglll-BsiWI-BbrPI-Notl-XhoI

Figure 7 pCLNC plasmid and its modifications. pCLNC was modified to contain a more useful multiple
cloning site. This was accomplished by ligating annealed 5’ phosphorylated primers into Hindlll-Clal cut
pCLNC. 2/5 Ncol sites present in pCLNCX are shown to aid in interpretation of figure 9.

Figure 8 The U3 region contains retroviral transcription factor binding sites. The U3 region lies at the
3’ end of the provirus, but is copied to the 5’end during reverse transcription, forming the 5’ LTR. It
contains the transcription factor binding sites responsible for promoting neo in the pCLNCx plasmid.
Several of these sites are removed in the SIN plasmid, which contains a several hundred bp deletion from
the U3 region. [Adapted from Heaphy, 1997]
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Not SIN (REG)
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SIN

REG (wjMCS) and
gp70p 15E insert

GFP
SIN

A.

4361

2322
2027

Figure 9 Ncol restriction digests of pCLNC plasmids. Ncol cuts pCLNCx in 5 places, but does not cut
GFP or gp70pl5E. The SIN plasmid contains a several hundred bp deletion from the U3 region. The Ncol
fragment containing the U3 region also contains the multiple cloning site and any insert. Therefore, the
size of this band indicates whether the plasmid is SIN or non-SIN, and the size of inserted gene. The lanes
are as follows: pCLNCx (SIN Lane 1, Non-SIN Lane 2, Non-SIN w/ multiple cloning site Lane 3),
pCLNCGFP (SIN) Lane 4, and pCLNCgp70pl5E (Non-SIN) Lane 5. GFP is 800bp, gp70pl5E is 2009bp.

To manufacture pseudotyped virus, the pCLNC plasmid and a plasmid encoding
the VSV-G envelope protein were co-transfected into semi-confluent 293GP cells using
commercially available lipofectamine reagents (GIBCO). Serial supernatant harvests of
the virus were performed on days 2,3,4 and 5 post-transfection, passed through a 0.45 pm
filter (Millipore) and frozen. Supernatants were thawed on the day of transduction and
concentrated in an ultracentrifuge (50,000g, 1.5 hrs, 4°C). The viral pellet was gently
resuspended to achieve appropriately concentrated virus.
One day after bone marrow harvest, concentrated supernatant containing VSV
pseudotyped retrovirus (described above) was added to the dendritic cells along with 8
ug/ml polybrene (Sigma) and lOmM HEPES (Biofluids). Transduction was performed
by spinoculation on a table-top centrifuge for 1 hour (2800 RPM, 32°C).
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Adenoviral Vectors and Adenoviral Transduction of DCs
The recombinant adenoviral vectors Ad.GFP and Ad.hgplOO were a gift from
Bruce Roberts (Genzyme) and are described in detail elsewhere42. These Ad vectors were
derived from Ad serotype 2, and a CMV promoter driving expression of the transgene
was inserted into the deleted El region.

The adenovirus was thawed on the day of

transduction.
Recombinant adenovirus was added at an MOI of 500 to the dendritic cells after
replating on day 6. The transduction was carried out for 24 hours at 37°C, 5% C02.

Animals
Murine class II-deficient, DR4-IE transgenic mice express chimeric class II
molecules consisting of the antigen binding domains from HLA-DRA and and HLADRB1*0401 molecules and the remaining domains from murine IEd-a2 and IEd-(32
chains43 (figure 10). This allows these animals to present HLA-DRB1 *0401 epitopes
while preserving the species-specific interaction between the murine CD4+ molecule and
the P2 domain of the murine MHC Class II molecule. These animals were obtained from
Taconic and maintained in accordance with institutional standards. C57BL/6n (H-2b)
mice were obtained from the Frederick Research Center.
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DR4-IE Chimeric Class II MHC
(Murine Class II KO)

Figure 10 DR4-IE transgenic mice.

These mice are murine class II knockouts; they have chimeric class

II molecules consisting of the antigen binding domains from HLA-DRA and HLA-DRP1 *0401 molecules,
and the remaining domains from murine IEd-a2 and IEd-p2 chains. Figure adapted from Ito, 1996.

Tumors and Cell Lines
The spontaneous murine melanoma B16 expresses the known tumor antigens
gplOO, MART-1, tyrosinase, Trp-1 and Trp-2. MC38 is a moderately immunogenic
colon adenocarcinoma that was generated by administration of oral 1,2-dimethhydrazine
in C57BL/6 mice. MC38 is known to present an antigen to MC38 TIL derived from the
endogenous retrovirus envelope protein, pl5E 44. The melanoma cell line 526 expresses
gplOO at high levels, and is frequently used as a positive control for gplOO recognition
assays. 3T3-CD40L and 3T3-SAMEN are 3T3 cells retrovirally transduced with murine
CD40L and SAMEN, respectively. SAMEN is an irrelevant retroviral protein, and is
used in these experiments as a negative control for 3T3-CD40L mediated dendritic cell
activation. All tumor lines were maintained in RPMI medium with 10% heat-inactivated
fetal bovine serum, 0.03% L-glutamine, 100 pg/ml of streptomycin, 100 pg/ml of
penicillin and 50 pg/ml of gentamicin sulfate (NIH media center).
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Dendritic Cell Harvest and Differentiation
By harvesting mouse bone marrow, depleting the marrow of all ells except stem
cells, and then differentiating those cells in the presence of GM-CSF and IL-4, dendritic
cells are produced45. These cells can be transduced prior to proliferation with a retrovirus,
or after proliferation with an adenovirus (figure 11)
Harvest Bone Marrow from DR4-IE Transgenic Mice

T

Deplete cells expressing CD8, CD4, B220, and I-Ab
using mAbs and complement

Transduce with retrovirus
day 1, 3

t
Culture 6 days in GMCSF and IL-4

Transduce with adenovirus
day 6
Replate and Activate
with 3T3-CD40L or 3T3-SAMEN
Figure 11 Dendritic cel! manufacture and transduction. Dendritic cells are made by harvesting the
bone marrow of mice and depleting it of all except stem cells. Growing the stem cells in GMCSF and IL-4
differentiates them into dendritic cells. They can be transduced with a retrovirus prior to proliferation or
transduced with adenovirus afterwords.

Bone marrow was expelled from the long bones of C57BL/6 or DR4-IE mice.
Erythrocytes were depleted in ACK lysing buffer (Biofluids). Cells expressing B220,IAb,d, Lyt-2.2 and CD4+ were removed using hybridoma supernatant from TIB-146, TIB229, TIB-150, TIB-207 (ATCC) followed by incubation with rabbit complement
(Cedarlane). The remaining cells were plated at a concentration of 7xl05 cells/ml in 6
well plates, and cultured for six days in DC medium (RPMI supplemented with 5%
inactivated FCS (GIBCO), 2 mM glutamine (Biofluids), 100 U/ml penicillin and
lOOug/ml streptomycin (Biofluids) and 5x1 O'5 M 2-ME (Sigma)). Recombinant murine
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GM-CSF was added to a final concentration of 20 ng/ml (Peprotech) and recombinant
murine IL-4 (Peprotech) added to a final concentration of 100 ng/ml. Cytokines were
replenished on days 2, 4 and 6. On day 6, non-adherent cells were collected and replated
at 1 x 106 cells/ml in a 6 well plate. Where indicated, the cells were replated onto
irradiated 3T3 cells expressing CD40L or SAMEN (as a control for the CD40L
activation). On day 7, the non-adherent cells were collected and washed three times in
PBS before use.

Murine gplOO Specific CD8+ T Cell Lines
The generation of the CD8+ T cell clone specific for the H-2Db restricted epitope
of gplOO (gp 10025_33) used in this experiment has been described in detail elsewhere
(Overwijk, 1998). They were derived from splenocytes of mice immunized by gene gun
with human gplOO DNA. This line was thereafter restimulated with irradiated syngeneic
splenocytes pulsed with lpM mouse gpl0025.33 peptide. These cells are able to recognize
both human and murine gpl0025.33 epitopes presented on Db molecules, despite a three
amino acid difference between the murine and human epitope. All T cells were used
between 5 and 10 days after re-stimulation.

Murine gplOO Specific CD4+ T Cell Lines
The generation of the CD4+ T cell line specific for the HLA-DRB1 *0401 gplOO
epitope used in this experiment has been described in detail elsewhere (Touloukian,
2000). They were derived from DR4-IE transgenic mice which were originally
immunized with hgplOO protein. Cells were subsequently stimulated with irradiated
syngeneic DR4-IE splenocytes pulsed with hgpl0044.59.
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Tumor Infiltrating Lymphocyte Lines
The MC38 reactive TIL used in this project have been described elsewhere46.
These TIL are known to recognize a class I epitope encoded on the endogenous ecotropic
murine leukemia virus, pl5E. The B16 TIL were isolated by Dr Michael Kershaw from
mice bearing subcutaneous B16 tumors which were retrovirally transduced with the B-7.1
co-stimulatory molecule. All TIL lines were re-stimulated with irradiated tumor every
week, and supplemented with IL-2 every other day.

Creation of Tumor Retroviral Library
A high quality cDNA library was made from 1987 MC38 and cloned into a
pCLNCx retroviral construct by the method schematized in figure 12, using enzymatic
reagents from GIBCO and custom primers.
mRNA
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Not 1 primer-adapter
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-TTTTTT
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Second strand synthesis
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No 11
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t
f.
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Ligation to Plasmid pCLNC, Hindlll-Notl cut

Figure 12 pCLNCMC38 library construction.

AAAAAA
TTTTTT

pCLNCMC38 was created by first and second strand

synthesis from MC38 polyA mRNA, followed by ligation into pCLNC cut with Hindlll and Noth

The pCLNC plasmid used for ligation was prepared from a Hindlll-Notl digest of
pCLNCGFP (Non SIN) plasmid, which was purified by agarose gel. Thus, the library
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background resulting from autoligation of incompletely cut plasmid should be
pCLNCGFP rather than empty pCLNC. This was done so that the self-ligation
background could provide a useful parameter via fluorescence (by FACS or examination
under UV scope) to assess the efficiency of gene expression during pooled transduction.
Post-ligation colony counts are given in figure 13. This library is abbreviated as
pCLNCMC38.
Elution fraction
1-1
1-2
1-3
11-1
11-2
11-3
plasmid only (V)

10 uL
66
160
242
154
234
252
2

IOOuL
-500
>500
>500
>500
>500
>500
80

Figure 13 pCLNCMC38 library post-ligation colony counts. The different ligation conditions and
elution fractions were electroporated into bacteria to characterize their insert to background ratio. These
colony counts of pCLNCMC38 show a high quality library with low (plasmid only) background. Roman
numerals (1,11) indicates the elution fraction of polyA mRNA used in library synthesis. Arabic numerals
(1,2,3) indicate different ligation conditions into pCLNC plasmid.

Hindlll and Notl digests (liberating cDNA insert) were performed on 18 colonies
chosen at random. Gel electrophoresis (figure 14) and sequencing (figure 15) of these
randomly selected clones confirms that they contain a wide variety of genes, with a good
range of insert sizes. A significant portion of the cDNA inserts include a start codon.
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1018

4072
3054
2036
1630
1018

Figure 14 pCLNCMC38 library insert sizes. Gel electrophoresis of 18 randomly selected colonies from
pCLNCMC38 library after restriction digest to liberate insert. This gel demonstrates a variety of cDNA
insert sizes, from 800 bp to 3500+ bp.
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11-3 17
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TOT
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<= 50

Figure 15 pCLNCMC38 library characterization. The same 18 randomly selected colonies shown in
figure 14 were sequenced for the first several hundred base pairs. These sequences were then matched for
known homology by BLAST search. When known, the existence or lack of a start codon is noted.
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Immunization of Mice Against MC38 Using Dendritic Cells Transduced en
masse with an MC38 cDNA Library
Dendritic cells from C57BL/6 mice were transduced two times with
pCLNCMC38 or pCLNCGFP.

MC38 transduced dendritic cells were injected into the

footpads of C57BL/6 mice. Control mice were injected with equivalent numbers of GFP
transduced dendritic cells on the same schedule. Three separate immunizations of 3x106
DCs were given on days 0, 13 and 15. These mice were randomized after immunization.
Mice were challenged with subcutaneous bilateral tumors approximately 3 weeks after
the final immunization with 2x10s MC38 cells. The MC38 used in the tumor challenge
was harvested from tumor-bearing mice in order to avoid anti-fetal calf serum mediated
effects. Tumor growth was measured bilaterally on days 4, 7, 9, 11, 13, 18 and 21.

IFN-y Release Assay
After the final dendritic cell harvest on day 7, lxl0s viable T cells and 1x10s
dendritic cells were incubated in duplicate for 12 hours in 96 well plates. The murine
IFN-y concentration in the supernatant was determined by ELISA, using commercially
available reagents (Endogen).

Recognition was considered significant when IFN-y

secretion was greater than twice the appropriate background measurement. Significant
values are bolded in tables.

Peptides
Peptides used in recognition assays were pulsed onto dendritic cells then washed
four times in PBS prior to use in recognition assays. They were synthesized by Surgery
Branch technicians and confirmed by mass spectroscopy. Human gpl 0025.33:
KVPRNQDWL, human gpl0044.59: RQLYPEWTEAQRL, pl5E604.611 (MHC Class I
irrelevant control peptide): KSPWFTTL, HA (MHC Class II irrelevant control peptide).
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RESULTS
Dendritic Cells Derived from Mouse Bone Marrow can be Efficiently
Transduced Using Adenovirus and VSV-G Pseudotyped Retrovirus
To determine how amenable dendritic cells are to gene transfer using these
methods, DCs were transduced with genes for GFP or human gplOO. To determine
whether the transduced cells efficiently expressed the transgene, a FACS analysis of the
GFP transduced cells was performed (figure 16). Both adenovirally and retrovirally GFP
transduced cells displayed cell surface markers similar to non-transduced dendritic cells.
Specifically, the dendritic cells were strongly positive for CD1 lc, B7.1 and B7.2
expression (data not shown). For the purpose of calculating transduction efficiency, any
CD1 lc+, GFP+ cells were considered to be GFP transduced dendritic cells.
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Adenovirally Transduced

Rctrovirally Transduced
Non-transduccd

GFP Transduced, CDlle+

GFP Transduced, 0)1 lc+

Figure 16 Adenoviral and retroviral transduction of dendritic cells with GFP. The green fluorescent
protein (GFP) was inserted into dendritic cells using either a VSV-G pseudotyped retrovirus or an
adenovirus. RatIgG2a is the isotype control for the antibody recognizing murine CD1 lc. Retrovirus was
more efficient than adenovirus at transducing these dendritic cells.

For retrovirally transduced dendritic cells, the number and timing of
transductions, along with the titer of the viral supernatant, determined the level of
transgene expression in cells (figure 17). More frequent transductions with more
concentrated supernatant resulted in higher transgene expression (23% for one
transduction with unconcentrated supernatant vs. 79% for two transductions with lOOx
concentrated supernatant), but resulted in fewer dendritic cells per mouse. This reduction
in dendritic cell yield most likely reflects direct toxicity from the VSV envelope or injury
from the polybrene or spinoculation process.
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Unconcentrated

Concentrated lOOx

dl

23% GFP, CD1 lc+

79% GFP, CD1 lc+

Figure 17 Transduction number and virus concentration affects transgene expression in DCs. The
number of transductions and concentration of supernatant determines the level of transgene expression in
retrovirally transduced dendritic cells.

Efficiency of adenoviral transduction of dendritic cells was related to the quality
of the adenovirus used. In all circumstances, however, retroviral transduction resulted in
higher levels of transgene expression than with adenoviral transduction, as measured by
GFP fluorescence.

DR4-IE Dendritic Cells can be Transduced with Adenovirus and VSV
Pseudotyped Retrovirus, and express DR4
Dendritic cells derived from the bone marrow of DR4-IE mice were efficiently
transduced with genes for GFP or human gplOO, using adenovirus or retrovirus (figure
18). GFP expression in retrovirally transduced cells was stronger than GFP expression in
adenovirally transduced cells. In addition to the cell surface markers described above
(CD1 lc, B7.1 and B7.2), these DCs were strongly positive for HLA-DR, indicating the
presence of the chimeric MHC class II molecule on the surface of these cells.
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Figure 18 DR4-IE Dendritic cell transduction. DR4-IE dendritic cells transduced with GFP using a
VSV-pseudotyped retrovirus or an adenovirus have good transgene expression, and are strongly positive
for HLA-DR. Thick lines indicate FACS histogram of gplOO transduced dendritic cells, thin line indicates
GFP transduced dendritic cells.

Dendritic Cells Can Be Transduced With Pools of Genes Using VSV
Pseudotyped Retroviral Vectors

Fluorescence studies
To assess the behavior of individual transgenes transduced into dendritic cells
with pools of other genes, the pCLNCGFP plasmid was diluted in empty pCLNCX
plasmid prior to transfection of 293GP cells. This was done at ratios of 1:0 (i.e. 1 part
pCLNCGFP to 0 parts pCLNCX), 1:10, 1:100 and 1:500. Since 293GP cells transfected
with pCLNCX make a retrovirus with titers comparable to pCLNCGFP (data not shown),
this provides a convenient model for assessing the behavior of individual transgenes in a
pool. Assuming that pCLNCGFP represents the gene of interest, and that pCLNCX
represents all other genes, the cell’s fluorescence indicates the level of expression of an
individual transgene in a gene pool whose size is determined by the dilution ratio. The
dendritic cells in this experiment were transduced using unconcentrated supernatant, on
day 1 only. Transduction efficacy could be improved by more frequent transductions or
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more concentrated supernatant. The FACS analysis shows GFP expression, albeit at low
levels, even at a pool size of 500 (figure 19). This indicates that transgene expression
persists in large pools, but decreases rapidly with increasing pool size.
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Figure 19 Dendritic cell transduction with gene pools. FACs analysis of dendritic cells transduced with
pools of genes. PCLNCGFP plasmid was diluted in empty pCLNCx plasmid at the ratio given prior to
transfection into 293GP cells. At a pool size of 1:100, 1% of dendritic cells are expressing an individual
transgene.

Recognition Studies
Recognition studies were used to demonstrate that transduced dendritic cells can
express and present individual transgenes to T cells, even when they are transduced using
large pools of genes. The plasmid pCLNCgplOO was diluted in pCLNCGFP plasmid
prior to transfection into 293GP cells. This was done at ratios of 1:0 (pCLNCgplOO
only), 1:10, 1:100, 1:1000, and 0:1 (pCLNCGFP only). In this model, specific
recognition of gplOO indicates the presentation of an individual transgene in a gene pool
whose size is determined by the dilution ratio.
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The unconcentrated supernatant was used to transduce the dendritic cells on day 1
only, and then lxlO5 mature dendritic cells were used in a IFN-y release assay with lxlCP
CD8+ T cells specific for the gpl0025.33 epitope. These pooled data demonstrate that
gplOO transduced dendritic cells efficiently present antigen at a pools size of 100, but not
a pool size of 1000 (figure 20).
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Figure 20 Recognition of Dendritic cells transduced with gene pools. Dendritic cells transduced with
supernatant derived from pCLNCgplOO diluted in pools of pCLNCGFP prior to 293GP transfection are
recognized by gplOO specific CD8+ T cells at a pool size of 1:100 but not 1:1000.

A Murine CD8+ T Cell Clone Specific for hgpl0025_33 Recognizes hgplOO
Transduced Dendritic Cells
To determine if the transduced DR4-IE dendritic cells were able to process and
present a class I epitope encoded by the transgene, a murine CD8+ T cell clone specific to
the H-2Db epitope of gplOO (hgpl0025.33) was used in a cytokine release assay with gplOO
transduced dendritic cells. This clone was able to specifically recognize the gplOO
transduced dendritic cells above GFP transduced DC controls, for both adenovirally and
retrovirally transduced cells (figure 21). Recognition of retrovirally transduced dendritic
cells was greater than that of adenovirally transduced dendritic cells. Numbers given are
results from a representative experiment. For controls, the CD8+ T cells recognized DCs
pulsed with gpl0025.33 peptide over DCs pulsed with an irrelevant MHC class I peptide
(pi5E604_61,). These findings indicate that transduced dendritic cells can efficiently present
transgene-encoded epitopes along the endogenous pathway.
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Figure 21 CD8+ recognition of gplOO transduced dendritic cells. The CD8+ T cell clone specific for
gpl0025_33 recognized adenovirally and retrovirally gplOO transduced dendritic cells more than GFP
transduced controls. DCs pulsed with gpl0025.33 peptide were recognized more than DCs pulsed with an
irrelevant H-2Db epitope.

A Murine CD4+ T Cell Line Specific for hgpl0044_59 Recognizes hgplOO
Transduced Dendritic Cells
DR4-IE dendritic cells identical to those used in the CD8* assay were used in a
cytokine release assay with CD4+ T cells recognizing the HLA-DRB1*0401 restricted
hgpl0044.59 epitope. These CD4+ T cells were able to specifically recognize the gplOO
transduced dendritic cells above GFP transduced controls, for both adenovirally and
retrovirally transduced dendritic cells (figure 22). This indicates that transduced dendritic
cells were also able to process and present a class II epitope from an endogenous antigen.
Again, recognition of retrovirally transduced dendritic cells was greater than that of
adenovirally transduced dendritic cells. DCs pulsed with gpl0044.59 peptide were
appropriately recognized over DCs pulsed with an irrelevant MHC class II peptide.
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Figure 22 CD4+ recognition of gplOO transduced dendritic cells. The CD4+ T cell clone specific for
gpl0044.59 recognized adenovirally and retrovirally transduced dendritic cells more than GFP transduced
controls. DCs pulsed with gpl0044.59 peptide were recognized more than DCs pulsed with an irrelevant
HLA-DR(3*0401 epitope.

CD40L Activation of Dendritic Cells Has Little Effect on Class I or Class II
Presentation of Trans gene
To determine whether further activation of the dendritic cells has any impact on
class I expression of the transduced dendritic cells, the gplOO or GFP transduced, DR4-IE
DCs were activated by replating them onto irradiated 3T3 cells expressing CD40L, or
3T3 cells expressing SAMEN.

lxlO5 dendritic cells were then incubated overnight with

lxlO5 gplOO specific T cells, and the cytokine concentration in the supernatant was
measured.
Regardless of means of transduction or their method of activation, both CD4+ and
CD8+ T cells were able to recognize gplOO transduced dendritic cells over their GFP
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transduced counterparts (figure 23).

Specific recognition of retrovirally transduced DCs

was higher than adenovirally transduced DCs in all cases. In this experiment, CD40L
activation seemed to have little effect on either class II or class I presentation, with the
possible exception of dampening CD4+ recognition of retrovirally transduced cells. This
finding may indicate that dendritic cells produced using the methods described above are
already maximally stimulated, and further activation may be non-productive.
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Figure 23 The effect of CD40L on antigen presentation in transduced dendritic cells. CD40L
activation of gplOO transduced dendritic cells had no reliable discemable effect on class 1 or class II
presentation of gplOO epitopes. In all cases, gplOO transduced DCs were recognized significantly more
than GFP transduced dendritic cells.

Lack of Protection Against MC38 Using Dendritic Cells Transduced en
masse With an MC38 cDNA Library
Dendritic cells were transduced with an entire MC38 cDNA library (one
transduction only, using 1 Ox concentrated supernatant) and then used in a recognition
assay with MC38 TIL. The results are given in figure 24. Although MC38 TIL
recognition of MC38 transduced DCs was higher than that of GFP transduced DCs, this
recognition did not reach significance (twice background). This finding is not
unexpected, given the scarcity of antigens recognized by 38 TIL and the very large
number of plasmids in the library.
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Figure 24 Lack of Recognition of dendritic cells transduced with MC38 library. MC38 TIL do not
significantly recognize dendritic cells transduced with an entire pCLNCMC38 library above GFP
transduced dendritic cell controls. Both MC38 TIL and B16 TIL recognize tumor as positive controls for
the T cells.

The MC38 or GFP transduced dendritic cells were injected into the foot pad of
mice for a total of three immunizations over 15 days. These mice were randomized and
challenged subcutaneously with a reliably tumorigenic dose of freshly isolated MC38
tumor. Results of tumor growth measurements are given in figure 25. There are no
significant differences in tumor growth between mice immunized with GFP transduced
dendritic cells or dendritic cells transduced with the MC38 library.

This indicates that

DCs transduced with an entire MC38 cDNA library were an ineffective means of
immunizing against MC38 tumor.
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Figure 25 Lack of protection from MC38 by immunization with MC38 transduced dendritic cells.
Repeated immunizations with pCLNCMC38 transduced dendritic cells failed to protect mice against
subcutaneous MC38 tumor challenge beyond immunization with pCLNCGFP transduced dendritic cell
controls.

Discussion
VSV-G Pseudotyped Retroviral Transduction Efficiency
The relative ease of dendritic cell transduction and high levels of transgene
expression obtained with VSV-G pseudotyped retroviral vectors is evident throughout
these experiments. It is crucial to interpret these transduction efficiencies with caution,
since experience with these retroviral constructs suggests that viral titer depends greatly
on the size and properties of the insert. For example, pCLNCx (no insert), pCLNCgplOO
(2 kb insert) and pCLNCGFP (800 bp insert) all give unconcentrated titers of 107 colony
forming units (cfu)/ml but pCLNCgp70pl5E (2.2 kb) produced unconcentrated virus with
a much lower titer, 105 cfu/ml. This is perhaps due to unusual tertiary structure in the
gp70pl 5E RNA, or secondary to interference from the pl5E gene product with viral
budding from the virus-producing cell. A plasmid containing a much larger insert,
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pCLNCPgal, produced an intermediate viral titer of 106 cfu/ml. These variations in viral
titer caution against inferring the transduction efficiency of one construct using data
extrapolated from the transduction efficiency of another plasmid.
Even taking into account the variability between specific retroviral plasmids, and
the differences between batches of adenoviral vectors, VSV-G pseudotyped retroviral
vectors consistently outperformed adenoviral vectors in both fluorescence and
recognition assays of gene transfer efficiency.

This suggests that other investigators may

wish to use pseudotyped retroviral vectors as a convenient, efficient means of dendritic
cell transduction.

MHC Class I and Class II Presentation of Tumor Antigen in Transduced
Dendritic Cells
The data presented here demonstrate that adenovirally and retrovirally transduced
dendritic cells are capable of presenting class I and class II epitopes of the melanocyte
differentiation antigen, gplOO. CD40L activation of the dendritic cells had little impact
on their ability to present either epitope, perhaps reflecting the mature state of the
dendritic cells prior to biochemical manipulation. These findings join a growing body of
evidence suggesting that gene-modified dendritic cells can present both MHC class I and
class II epitopes, and therefore may be a means to simultaneously initiate a CD4+ and
CD8+ anti-tumor response.
As discussed in the introduction, gplOO contains a melanosome transport signal
(MTS) known to traffic antigens to the endocytic pathway for class II presentation. What
role, if any, the transport signal plays in the class II epitope presentation of this epitope is
not known.

Furthermore, the class II presentation of any given cytoplasmic antigen must
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be determined individually, as it involves many factors, including the rapidity of protein
turnover in the cytosol47. Because of these caveats, class II presentation of all
endogenous antigens cannot be presumed from the finding that transduced dendritic cells
are capable of presenting a gplOO derived class II epitope. Nonetheless, it would be
important to compare the abilities of different targeting signals (MTS, LAMP and the
Invariant chain) to augment class II presentation. This may allow investigators to
generalize about the most efficient class II targeting signal, and take this into account
when designing the constructs used for dendritic cell transduction.

The Potential for Using Dendritic Cells Transduced with Pools of Genes to
Find New Tumor Antigens
These data demonstrate that dendritic cells can be efficiently and simultaneously
transduced with large numbers of genes using VSV-G pseudotyped retrovirus. This was
shown both using FACS data gathered from cells which were transduced with
pCLNCGFP diluted in pCLNCX and using recognition data of cells transduced with
pCLNCgplOO diluted in pCLNCGFP. The ability to transduce DCs with pools of genes,
combined with the ability to protect mice from tumors after immunization with
transduced dendritic cells may provide a new and important means of discovering tumor
antigens.
By immunizing mice with DCs transduced with pools of genes encoding potential
antigens obtained from a tumor and then challenging immunized mice with that tumor,
one could identify mice that were protected from tumor challenge. The antigen
responsible for that protection could then be isolated from the original gene pool by
repeated rounds of sub-pooling and tumor challenge (as shown in figure 5). The
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importance of this method is that it uses tumor rejection as its endpoint, and therefore
discerns only potentially useful rejection antigens.

It can be applied to any type of

tumor, and may give an indication of which types of cancers will prove ultimately
amenable to immunotherapy. The system also overcomes a major drawback in current
antigen finding methods, which only identify the subset of antigens recognized by T cells
that have a high precursor frequency in peripheral blood or infiltrate tumors in vivo.
The recent push to develop better murine models for human cancers will result in
more tumor models amenable to immunotherapy work and antigen discovery using these
techniques. For example, current breast cancer models are generally inappropriate for
immunotherapy study, because they depend on tumors induced by the murine mammary
tumor virus (MMTV). MMTV greatly alters the antigen profile on the tumor, and does
not have a clinically relevant human counterpart. Once better models are acquired, the
antigens discerned from work in mice may have homologous human antigens, as was
found to be the case with melanoma.
The major disadvantage to this method of antigen finding is that it is
extraordinarily labor intensive. Given the evidence that individual transgenes are
expressed in > 1% of cells and capable of being effectively presented on DCs at a pool
size of 100, this is an appropriate pool size for initial screening. Assuming that
approximately 20,000 genes are expressed in a well-differentiated cell1, it would require

1 The number of genes expressed in a given cell varies greatly depending on its tissue type and condition.
For example, human kidney expresses 19477 genes, 3034 of which are unique (only 30 of the unique genes
are known). The best estimates come from expressed sequence tag (EST) databases, available on line at
the Cancer Genome Anatomy Project (http://www.ncbi.nlm.nih.gov/CGAP/hTGI/sumtab/cgapba.cgi). As
preliminary analyses of the human genome project draft arrive (International Human Genome Sequencing
Consortium, Nature 409: 860-921,2001), it appears that the EST databases have overestimated the number
of genes present in any given cell.
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200 pools to thoroughly screen the library. Even this would not ensure that all antigens
have been screened, as more common genes would be included multiple times, while less
common genes may not be included in the screening at all.
There are a number of strategies that could reduce the number of potential
antigens needing to be screened using this method.

Through library subtraction

techniques, one could develop a pool of genes expressed in a neoplastic cell but not in a
normal cell of the same tissue type from the same patient.

This method would more

efficiently identify potential antigens that have become activated during oncogenesis, e.g.
embryonic antigens, and would obviate the need to screen extremely common genes, such
as actin, that have little to no potential for tumor-selective antigenicity. Unfortunately,
using the same tissue type for library subtraction would prevent the identification of
normal differentiation antigens and mutated antigens, as these genes would be removed
during subtraction.

This process can be visualized and analyzed using bioinformatics

tools, such as digital differential display48. Variations on this idea produce slightly
different results. For example, subtracting the library of the tumor cell from a different
cell type would enrich for differentiation antigens, but still eliminate mutated antigens of
proteins shared by the cell types.

Dendritic Cells Transduced with Genetic Material Obtained from Tumor as
a Means of Tumor Protection
In these experiments, mice were immunized with dendritic cells transduced en
masse with a tumor cDNA library from MC38, and then challenged with the
corresponding MC38 tumor. This immunization resulted in no protection from tumor
challenge beyond control mice immunized with GFP transduced dendritic cells. Given
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the data in figure 20 demonstrating the lack of specific recognition of dendritic cells
transduced with gplOO in gene pools of 1000, the lack of immunization by DCs
transduced with a much larger gene pool (the 38,400 plasmid library) is not entirely
surprising.

A more vigorous schedule of immunization with similarly transduced

dendritic cells is unlikely to result in protective immunity.
An intriguing question is how less efficient strategies for gene-modifying DCs
were able to generate protective immunity. For instance, a group has reported for a
number of different tumor types that dendritic cells transfected with RNA obtained
directly from the tumor are able to immunize mice despite transient and mediocre
amounts of transgene expression49. The difference cannot be explained by relative over¬
representation of antigens in RNA, as they should be proportionately represented in a
tumor cDNA library. Given the data described in these experiments, it is difficult to
imagine that an antigen in a complete library of RNA (driven by weaker, physiologic
promoters) will be expressed at useful levels, even transiently. It would be important to
validate these approaches using pooled transfections similar to those described in this
paper before proceeding to clinical trials of RNA transfected DCs. The recent, well
publicized50 work on poorly characterized tumor cell-dendritic cell hybrids51 raises similar
concerns.

Identifying and cloning antigens recognized by the T cells involved in the

anti-tumor response remains the gold standard for validating immunization methods. The
many groups that claim success in immunizing patients with dendritic cells transfected
with genetic material obtained directly from tumor have yet to meet this standard.
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Conclusion
The same qualities that make dendritic cells ideal for initiating an immune
response to infection make them attractive for generating an anti-tumor immune response.
The simplicity of this logic has sparked manifold experiments in animals and humans
using antigen loaded DCs for the immunotherapy of cancer. Data on the efficacy of
tumor antigen presentation to T cells by dendritic cells is rapidly accumulating. Amongst
these data, there is increasing evidence that gene-modified dendritic cells are an efficient
means of presenting both class I and class II tumor antigens.

The data presented in this

paper strongly support this assertion.
Each APC must present antigen on its surface at levels detectable by T cells. The
most efficient known method of DC transduction is described in this paper, but is still
unable to raise protective immunity using DCs transduced with entire tumor libraries.
These experiments describe the importance of delineating individual trasngene expression
and antigen presentation in cells modified with tumor-derived genetic material.
The anti-tumor immune response has limitations that cannot be circumvented
through more efficient antigen presentation. Although dendritic cells in general, and
transduced dendritic cells in particular, show promise as a means of presenting tumor
antigens to T cells, they will not overcome problems related to tolerance, tumor escape, T
cell suppression and improper T cell trafficking and activation. While these considerable
barriers are being studied, transduced dendritic cells may prove useful for antigen
discovery and gaining insight into the anti-tumor immune response.
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